A
Aposense
Represents a new approach to harness a natural biologic pathway called RNA interference
About Aposense
Aposense is an Israeli biotechnology company specializing in the development of a universal platform called Molecular Nano Motors (MNMs) for the delivery of genetic drugs, such as siRNA, into cells. The company leverages a novel mechanism of action that utilizes membrane electrical forces, specifically the Membrane Dipole Potential, to achieve this. Aposense operates in the genetic therapeutics market, serving pharmaceutical companies and research institutions focused on genetic medicine. The business model revolves around licensing its technology to these clients, thereby generating revenue through licensing fees and potential royalties from successful drug applications. The company is led by Professor Roger D. Kornberg, a Nobel Prize Laureate, and boasts full-capacity research facilities to support its innovative endeavors.
Source: Dealroom company dataAt a glance
- Founded
- 1996
- Headquarters
- Petah Tikva, Israel
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Pontifax Funds
Ziegler Meditech Equity Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aposense on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aposense on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.